Prof Maury presents, at a press conference at ASH 2015, results of the GRAALL-R 2005 study in which the addition of rituximab to standard chemotherapy was found to improve the outcome of adult patients with CD20-positive, Ph-negative, B-cell precursor acute lymphoblastic leukaemia (ALL).

The primary endpoint of event-free survival was increased from 52% with standard chemotherapy to 65% at 6 years when rituximab was added, Dr Maury says. Overall survival was about 60%. The latter appeared higher if patients who had received an allogeneic stem cell transplant at the time of their first complete remission were censored from the analysis.

Read the news story or watch the video interview for more information

Read the news story for more information.